STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

ABUS Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 10.4M shares, representing 6.2% of Arbutus Biopharma Corp in this filing.

FiledFeb 12, 2024
Ownership dateDec 31, 2023
Reported shares10.4M
Reported ownership6.2%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 10.4M
Shared voting power 10.4M
Sole dispositive power 10.4M
Shared dispositive power 10.4M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$2.87as of Feb 12, 2024
Latest tracked price$4.42as of Aug 4, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0001364742
Accession
0001086364-24-006950
Form
Schedule 13G/A
Open SEC filing View ABUS ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →